Outpatient Surgery Magazine

Calm & Cool in a MH Crisis - Subscribe to Outpatient Surgery Magazine - March 2018

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://outpatientsurgery.uberflip.com/i/954375

Contents of this Issue

Navigation

Page 38 of 124

the side of every MH cart and in a binder in every OR. We also created an MH cart policy so that we always had ready access to the many supplies you need in an MH crisis (see "What's In Your MH Cart?" on page 24). Many of the steps on the checklist will be familiar to anyone who has ever gone through an MH drill. But there are a couple aspects that I should highlight that are spe- cific to our institution and are key to our quick response. Our 5 MH carts The MH cart is the first thing that needs to get to the bedside. Like tanks on a battle- field, we positioned our 5 MH carts in strategic locations throughout the facili- ty. We perform sur- gery in 3 separate locations, so we placed a cart in each surgery wing. We have M a r c h 2 0 1 7 • O U T PA T I E N T S U R G E R Y. N E T • 3 9 Important Safety Information The use of The use of Revonto in the management of malignant hyperthermia crisis is not a substitute for previously known supportive measures. These measures must be individualized, but it will usually be necessary to discontinue the suspect triggering agents, attend to increased oxygen requirements, manage the metabolic acidosis, institute cooling when necessary, monitor urinary output, and monitor for electrolyte imbalance. Patients who receive i.v. dantrolene sodium preoperatively should have vital signs monitored. If patients judged malignant hype If patients judged malignant hyperthermia susceptible are administered dantrolene sodium preoperatively, anesthetic preparation must still follow a standard malignant hyperthermia susceptible regimen, including the avoidance of known triggering agents. Monitoring for early clinical and metabolic signs of malignant hyperthermia is indicated because attenuation of malignant hyperthermia, rather than prevention, is possible. Despite initial satisfacto Despite initial satisfactory response to i.v. dantrolene there have been reports of fatality, which involve patients who could not be weaned from dantrolene after initial treatment. The administration of i.v. dantrolene is associated with loss of grip strength and weakness in the legs, as well as drowsiness and dizziness. There have been reports of thrombophlebitis following administration of intravenous dantrolene. Tissue necrosis secondary to extravasation has been reported. Injection site reactions (pain, erythema, swelling), commonly due to extravasation, have been reported. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therap liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. To report SUSPECTED ADVERSE REACTIONS contact US WorldMeds at 1-888-900-8796 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.FDA.gov/medwatch/. To see the full prescribing information visit www.revonto.com. © 2017. US WorldMeds, LLC. Revonto is a registered trademark of US WorldMeds, LLC. REV-P91-0217 ® 36 month shelf life* Ready to administer in 20 seconds † Are You Prepared for a CRISIS? Visit www.revonto.com or call (877) 411-USWM (8796) to learn more and to see the full Prescribing Information. *from the date of manufacture † or until solution is clear

Articles in this issue

Links on this page

Archives of this issue

view archives of Outpatient Surgery Magazine - Calm & Cool in a MH Crisis - Subscribe to Outpatient Surgery Magazine - March 2018